Equity Profile

BIO

Bio-Rad Laboratories, Inc.

Health CareLife Sciences Tools & Services$7.9B

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:15 PM EDT

Bio-Rad Laboratories Misses on EPS, Stock Up 1.81%

Metric	Actual	Expected	Surprise
EPS	$1.89	$1.99	-5.0%
Revenue	N/A	$589M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Bio-Rad Laboratories Misses on EPS, Stock Up 1.81%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$1.89	$1.99	-5.0%
Revenue	N/A	$589M	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results. Therefore, management's messaging is unknown.

What It Means

Bio-Rad Laboratories reported earnings that fell short of expectations on EPS, which typically raises concerns among investors. However, the stock reacted positively, increasing by 1.81%. This could indicate that investors are optimistic about future performance despite the earnings miss, or that the market had already priced in lower expectations.

Company Snapshot

Bio-Rad Laboratories, Inc. is a global leader in life sciences tools and services, providing essential products for research and clinical diagnostics....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of a company's profitability and is closely watched by investors.

$1.99

Revenue

Revenue indicates the overall sales performance and market demand for Bio-Rad's products.

$589M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Bio-Rad Laboratories, Inc. is a global leader in life sciences tools and services, providing essential products for research and clinical diagnostics. As a key player in the health care sector, Bio-Rad's innovations support advancements in scientific research and medical testing, making it an important company in the ongoing growth of the life sciences industry.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+15.34%

Avg Stock Reaction

-1.01%

Last Quarter Recap

In the last quarter, Bio-Rad reported an EPS of $2.51, slightly missing analyst expectations. The stock reacted negatively, reflecting investor concerns about growth.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Bio-Rad to report earnings of $1.99 per share and revenue of $589 million for Q1-2026. The market is cautious due to recent earnings misses.

Bull Case

If Bio-Rad can exceed EPS expectations and show strong revenue growth, it could signal a rebound in demand for its products, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it may raise concerns about its growth trajectory and lead to further stock declines.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.99

EPS is a critical measure of a company's profitability and is closely watched by investors.

Revenue

$589M

Revenue indicates the overall sales performance and market demand for Bio-Rad's products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Bio-Rad's EPS exceed the consensus estimate of $1.99?

A beat on EPS could indicate a recovery in profitability and improve investor sentiment.

What revenue growth can Bio-Rad report against the consensus of $589 million?

Revenue performance is crucial to assess the company's market position and demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Rad's ability to rebound from recent performance issues, as historical data shows a strong recovery potential.

Supporting Evidence

Bio-Rad has a history of surprising on the upside, with a 63% EPS beat rate over the last eight quarters.

The options market is pricing in a significant move, indicating that investors expect volatility and potential upside.

Recent insider activity, while routine, suggests confidence in the company's long-term prospects.

Key Risk

If revenue growth exceeds $600 million, it could significantly alter the market's perception of Bio-Rad's recovery potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a series of earnings misses, and investors are looking for signs of improvement.

Bull Confirmed If

An EPS of $2.10 or higher would confirm a strong recovery in profitability.

Bear Confirmed If

An EPS below $1.90 would suggest ongoing challenges and could lead to further declines.

Pre-Earnings Positioning

Options Market

Implied Move

±12.2%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.

Options are pricing ±12.2% while BIO has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

32.5%

Calls (0)P/C Ratio: 0.02Puts (300)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Rad beats expectations, history suggests the stock could see a positive reaction, potentially around +1.54% on the first day.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors weigh management's commentary against recent performance.

Miss

If the company misses expectations, history suggests a potential decline of around -1.89% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product demand trends in the life sciences sector.
2Management's commentary on cost management and profitability strategies.
3Insights into competitive positioning and market share.
4Details on any new product launches or innovations.
5Guidance for the upcoming quarters and any changes in market outlook.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

AVBReported

AvalonBay Communities, Inc.

RecapView

Apr27

CLSReported

Company Snapshot

Bio-Rad Laboratories, Inc. is a global leader in life sciences tools and services, providing essential products for research and clinical diagnostics....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of a company's profitability and is closely watched by investors.

$1.99

Revenue

Revenue indicates the overall sales performance and market demand for Bio-Rad's products.

$589M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+15.34%

Avg Stock Reaction

-1.01%

Last Quarter Recap

In the last quarter, Bio-Rad reported an EPS of $2.51, slightly missing analyst expectations. The stock reacted negatively, reflecting investor concerns about growth.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Bio-Rad to report earnings of $1.99 per share and revenue of $589 million for Q1-2026. The market is cautious due to recent earnings misses.

Bull Case

If Bio-Rad can exceed EPS expectations and show strong revenue growth, it could signal a rebound in demand for its products, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it may raise concerns about its growth trajectory and lead to further stock declines.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.99

EPS is a critical measure of a company's profitability and is closely watched by investors.

Revenue

$589M

Revenue indicates the overall sales performance and market demand for Bio-Rad's products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Bio-Rad's EPS exceed the consensus estimate of $1.99?

A beat on EPS could indicate a recovery in profitability and improve investor sentiment.

What revenue growth can Bio-Rad report against the consensus of $589 million?

Revenue performance is crucial to assess the company's market position and demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Rad's ability to rebound from recent performance issues, as historical data shows a strong recovery potential.

Supporting Evidence

Bio-Rad has a history of surprising on the upside, with a 63% EPS beat rate over the last eight quarters.

The options market is pricing in a significant move, indicating that investors expect volatility and potential upside.

Recent insider activity, while routine, suggests confidence in the company's long-term prospects.

Key Risk

If revenue growth exceeds $600 million, it could significantly alter the market's perception of Bio-Rad's recovery potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a series of earnings misses, and investors are looking for signs of improvement.

Bull Confirmed If

An EPS of $2.10 or higher would confirm a strong recovery in profitability.

Bear Confirmed If

An EPS below $1.90 would suggest ongoing challenges and could lead to further declines.

Pre-Earnings Positioning

Options Market

Implied Move

±12.2%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.

Options are pricing ±12.2% while BIO has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

32.5%

Calls (0)P/C Ratio: 0.02Puts (300)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Rad beats expectations, history suggests the stock could see a positive reaction, potentially around +1.54% on the first day.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors weigh management's commentary against recent performance.

Miss

If the company misses expectations, history suggests a potential decline of around -1.89% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product demand trends in the life sciences sector.
2Management's commentary on cost management and profitability strategies.
3Insights into competitive positioning and market share.
4Details on any new product launches or innovations.
5Guidance for the upcoming quarters and any changes in market outlook.